Robert Cozens
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, PI3K/AKT/mTOR signaling in cancer, Protein Kinase Regulation and GTPase Signaling, Angiogenesis and VEGF in Cancer, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase(2004)536 cited
- → New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis(2000)213 cited
- → Large‐scale purification and characterisation of a recombinant epidermal growth‐factor receptor protein‐tyrosine kinase(1992)30 cited
- → New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis.(2000)23 cited
- → Abstract 3859: Evaluation of addition of the tumor-vascular disrupting agent ASA404 (vadimezan) to paclitaxel and carboplatin and the influence of subsequent ASA404 maintenance therapy using a human NSCLC xenograft model(2010)1 cited
- → Supplementary Materials from JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2<sup>V617F</sup>-Driven Disease(2023)
- → Supplementary Figures 1-3 from Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging(2023)
- → Supplementary Figure Legends 1-3 from Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging(2023)
- → Supplementary Figure 2 from Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials(2023)